Survival Rate of Breast Cancer Based on Geographical Variation in Iran, a National Study

Abstract

BackgroundBreast cancer is the most common cancer among women worldwide. Based on the latest Iranian national cancer department report, the total number of women registered with breast cancer was 6976 cases during 2007. Five year survival is one of the indicators used for evaluation of the quality for care to different types of malignancies including breast cancer.ObjectivesThe aim of this study was to estimate survival rate of breast cancer in 6147 Iranian patients at a national level in different geographic regions.Materials and Methods6147 cases of breast cancer, which had telephone number and were diagnosed between 2001-2006, were called to obtain information about their life status. Survival estimates were calculated using the Kaplan-Meier method, and the survival probability was calculated for the overall cohort and in different categories of gender, age and pathologic type of tumor. Hazard ratios (HR) according to demographic and risk variables were calculated by Cox's proportional hazard model.ResultsThe overall 5-year survival rate was 71.0%. The mean survival time was different between men and women, which was statistically significant. The number of men involved with breast cancer was 172 (2.8%) of all cases. The 5-year survival rate for patients in age group 41-50 years was significantly higher than other age groups (P = 0.001). The likelihood of death was higher in patients with 61 years old or more years rather than those below forty years old (HR = 1.31; 95% CI: 1.12-1.55).ConclusionsThe findings of this study might help Iranian health managers: 1) to be more conscious about geographical and regional determinants which will affect overall survival rate. 2) To carry preventive activities such as public education particularly in Iranian men. 3) To think about screening and early detection of breast cancer.

Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival

“…Furthermore, Vahdaninia and Montazeri (2004) measured the total 5-year survival rate to be 62%, while in our study, it was reported to be 85% (26). Movahedi et al (2012) also calculated the 5-year survival rate to be 72% in BC patients during 2001 -2006 (27); differences in the time of these studies could explain this gap. (31).…”

“…(31). These disparities between the results can be justified by geographical variations in socioeconomic factors, quality of health services (27), and time differences between the studies.…”

Expression of EMSY, a Novel BRCA2-link Protein, is Associated with Lymph Node Metastasis and Increased Tumor Size in Breast Carcinomas

“…Breast cancer also ranks first among cancers diagnosed in Iranian women (Mousavi et al, 2009;Kolahdoozan et al, 2010;Movahedi et al, 2012).…”

Survival analysis of breast cancer patients with different chronic diseases through parametric and semi-parametric approaches

“…They identified 39 models for the survival analysis, determining risk factors for breast cancer. Metastasis [4,6,14,16,28,42], background of benign tumors [4], and age at diagnosis [4,5,16,INTRODUCTION 22,23,24,25,26,28,29,[32][33][34][35][36][37]39] were considered as the main factors in the survival analysis. Some studies emphasized on the factors such as hormone therapy (hormone receptor) [9,12,16,20,22,23,25,27,33,35,36,38], Her2 [9,11], grade [9,11,13,19,21,24,31,34,37,38], and lymph node involvement …”

“…Surgery [14,15,25,29,36] and CA 15-3 marker [15] are the other factors that can be considered in the survival analysis. Furthermore, the combination of the following factors have been suggested across different studies: familial history [24], smoking [24], affected side [20,39], place of residence [29], number of involved lymph nodes [22,24,27,31,34,35,37], stage [5,6,8,17,25,26,42], stage of surgery [25], tumor size [16, 19, 20-24, 27, 28, 31, 34, 35, 37, 38, 41], complete clinical and pathological response [41], medicine [29], type of pathology [32], type of treatment [17,21], chemotherapy [25,33,36,37], neoadjuvant chemotherapy [18], radiotherapy [25,33,36], number of metastasis [30], bone pain [30], and time interval leading to bone metastasis [42]. No study has considered chronic diseases as an effective factor of survival analysis.…”